*Biological Materials Availability:* Biological materials related to this technology are not available at this time.

Licensing Availability: This application is available for license on a non-exclusive or exclusive basis.

*Licensing Contact:* Susan S. Rucker; 301/435–4478; e-mail: *ruckersu@mail.nih.gov.* 

# Genes Expressed in Prostate Cancer and Methods of Use

Description of Technology: This invention is a novel gene, called New Gene Expressed in Prostate (NGEP). This gene appears to be expressed only in human prostate and prostate cancer. This gene has two known splice variants of significantly different size. The shorter splice variant encodes a cytoplasmic protein, while the longer splice variant encodes a plasma membrane protein, which has been detected on the plasma membrane of human cancer cells.

This patent application contains claims to the polypeptide, NGEP, nucleotides encoding NGEP, antibodies that bind NGEP polypeptides, and methods of using these polypeptides, polynucleotides, and antibodies.

The presence of the protein on the cell surface and the selective expression in prostate and prostate cancer make this a potential target for prostate cancer diagnostics and therapeutics. Potential therapeutics could be gene-based, vaccines, antibodies, or immunoconjugates.

*Inventors:* Ira Pastan, Tapan Bera, and Byungkook Lee (NCI.)

Publications:

1. S Das et al. NGEP, a prostatespecific plasma membrane protein that promotes the association of LNCaP cells. Cancer Res. 2007 Feb 15; 67(4):1594– 1601.

2. TK Bera et al. NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate. Proc Natl Acad Sci USA. 2004 Mar 2; 101(9):3050–3064.

Patent Status:

1. U.S. Provisional Application No. 60/461,399 filed 08 Apr 2003 (HHS Reference No. E–148–2003/0–US–01).

2. PCT Application No. PCT/US04/ 10588 filed 05 Apr 2004, which published as WO 2004/092213 on 28 Oct 2004 (HHS Reference No. E–148– 2003/0–PCT–02).

3. U.S. Patent Application No. 10/ 552,515 filed 06 Oct 2005 (HHS

Reference No. E–148–2003/0–US–03). *Licensing Status:* Available for non-

exclusive licensing.

Licensing Contact: Jesse S. Kindra, J.D.; 301/435–5559;

kindraj@mail.nih.gov.

Dated: February 22, 2007. **Steven M. Ferguson**, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7–3695 Filed 3–1–07; 8:45 am] **BILLING CODE 4140–01–P** 

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## National Institutes of Health

# Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Office of AIDS Research Advisory Council.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* Office of AIDS Research Advisory Council.

Date: April 19, 2007.

Time: 9 a.m. to 5 p.m.

*Agenda:* The meeting will focus on HIVrelated Complications including Malignancies, Cardiovascular Disease, and Metabolic Complications. An update will be provided on the OARAC Working Groups for Treatment and Prevention Guidelines.

*Place:* National Institutes of Health, 5635 Fishers Lane, Rockville, MD 20852.

*Contact Person:* Christina Brackna, Coordinator, Program Planning and Analysis, Office of Aids Research, Office of the Director, NIH, 5635 Fishers Lane MSC 9310, Suite 4000, Rockville, MD 20852, (301) 402– 8655, *cm53v@nih.gov.* 

Any member of the public interested in presenting oral comments to the committee may notify the Contact Person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Only one representative of an organization may be allowed to present oral comments and if accepted by the committee, presentations may be limited to five minutes. Both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's Center's home page: http://

www.ni.gov/od/oar/index.htm, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: February 23, 2007.

## Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–961 Filed 3–1–07; 8:45 am] BILLING CODE 4140-01–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

# Notice of Meeting: Secretary's Advisory Committee on Genetics, Health, and Society

Pursuant to Public Law 92-463, notice is hereby given of the twelfth meeting of the Secretary's Advisory Committee on Genetics, Health, and Society (SACGHS), U.S. Public Health Service. The meeting will be held from 8 a.m. to approximately 5 p.m. on Monday, March 26, 2007 and 8 a.m. to approximately 5 p.m. on Tuesday, March 27, 2007, at the Marriott Inn and Conference Center, University of Maryland-College Park, 3501 University Boulevard East, Adelphi, MD 20783. The meeting will be open to the public with attendance limited to space available. The meeting also will be Web cast.

The agenda will focus on the oversight of genetic testing, including the role of the private sector in assuring the quality and validity of genetic tests; the impact of gene patents and licensing practices on patient access to genetic technologies, including a progress report on the Committee's study; and the status of Federal genetic information nondiscrimination legislation. The Committee will be briefed on the Secretary's Personalized Health Care Initiative and the work of the American Health Information Community, particularly its Personalized Health Care Working Group. The Committee's report on the Policy Issues Associated with Undertaking a New Large U.S. Population Cohort Project on Genes, Environment and Disease will be

released at the meeting. There also will be updates on the Committee's draft report on pharmacogenomics and several Federal initiatives and activities.

Time will be provided each day for public comments. The Committee would welcome hearing from anyone wishing to provide public comments on any issue related to genetics, health and society. Individuals who would like to provide public comment should notify the SACGHS Executive Secretary, Ms. Sarah Carr, by telephone at 301-496-9838 or e-mail at sc112c@nih.gov. The SACGHS office is located at 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892. Anyone planning to attend the meeting, who is in need of special assistance, such as sign language interpretation or other reasonable accommodations, is also asked to contact the Executive Secretary.

Under authority of 42 U.S.C. 217a, Section 222 of the Public Health Service Act, as amended, the Department of Health and Human Services established SACGHS to serve as a public forum for deliberations on the broad range of human health and societal issues raised by the development and use of genetic and genomic technologies and, as warranted, to provide advice on these views. The draft meeting agenda and other information about SACGHS, including information about access to the Web cast, will be available at the following Web site: http:// www4.od.nih.gov/oba/sacghs.htm.

Dated: February 22, 2007.

#### Anna Snouffer,

Acting Director, NIH Office of Federal Advisory Committee Policy. [FR Doc. 07–965 Filed 3–1–07; 8:45 am] BILLING CODE 4140–01–M

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# National Institutes of Health

# National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate proposals for support through the RAID program by making available to the research community, on a competitive basis, NCI

new agent development contract resources for the preclinical development of drugs and biologics. The outcome of the evaluation will be a decision whether NCI should support the request and make available contract resources for support through the RAID program to the research community and NCI new agent development for the preclinical development of drugs and biologics. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel; Rapid Access to Intervention Development.

*Date:* March 20–21, 2007.

*Time:* 1 p.m.–5 p.m.

Agenda: To evaluate the Rapid Access to Intervention Development Portfolio.

*Place:* National Institutes of Health, Executive Plaza North, Conference Room J, 6130 Executive Boulevard, Rockville, MD 20852.

*Contact Person:* Phyllis G. Bryant, Executive Secretary, Program Analyst, Developmental Therapeutics Program, National Cancer Institute, NIH, 6130 Executive Boulevard, Rm. 8022, Bethesda, MD 20892. (301) 496–8720.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: February 22, 2007

### Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 07–968 Filed 3–1–07; 8:45 am] BILLING CODE 4140–01–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## National Institutes of Health

## National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Board of Scientific Counselors for Basic Sciences National Cancer Institute. The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Cancer Institute, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Scientific Counselors for Basic Sciences National Cancer Institute.

Date: March 4-5, 2007.

*Time:* March 4, 2007, 6 p.m. to 10:15 p.m. *Agenda:* To review and evaluate personal qualifications and performance, and competence of individual investigators.

*Place:* Double Tree Hotel, 8120 Wisconsin Avenue, Bethesda, MD 20814.

*Time:* March 5, 2007, 8 a.m. to 10 a.m. *Agenda:* To review and evaluate personal qualifications and performance, and competence of individual investigators.

*Place:* National Institutes of Health, National Cancer Institute, 9000 Rockville Pike, Building 31, Conference Room 6, Bethesda, MD 20892.

Contact Person: Florence E. Farber, PhD, Executive Secretary, Office of the Director, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 2115, Bethesda, MD 20892, 301–496–7628, ff6p@nih.gov.

This notice is being published less than 15 days prior to meeting due to scheduling conflicts.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: February 23, 2007.

### Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 07–970 Filed 3–1–07; 8:45 am] BILLING CODE 4140–01–M